MAPT and amyloidosis: When considering stratification of clinical trial participants for secondary prevention based on biomarker values, our data suggests amyloid PET CL of 30 (∼4 years after PET A+) or lower might be appropriate as this was the level at which p-tau217-positivity occurred on average, which may be indicative of amyloid-related tau hyperphosphorylation.